
## Stroke Prevention in AF patients :Edoxaban

## 온 영 근 삼성서울병원 성균관의대




## **Development of edoxaban**



\* Ki, binding affinity of the inhibitor


Hara et al. Thromb Haemost 1994;71:314–319; Fujii et al. Drug Metab Pharmacokinet 2007;22:26–32 Raskob et al. J Thromb Haemost 2013;11:1287–1294; Ruff et al. Am Heart J 2010;160:635–641 Morishima et al. Blood 2004;104: Abstract 1862; Yokoyama et al. Circulation 1995;92:485–491 Furugohri et al. J Thromb Haemost 2008;6:1542–1549


## Edoxaban does not induce CYP450 isozymes




. **Study design**: Randomized, parallel group, multi-dose, active-controlled, double blind edoxaban, open-label warfarin


**. Primary endpoint**: occurrence of major and/or clinically relevant non-major bleeding, elevated hepatic and/or bilirubin






\*Treatment group discontinued early based on recommendation by data safety monitoring committee






AUC, area under the plasma concentration-time curve from 0 to 24 hours at steady-state; C<sub>max</sub>, maximum steady-state plasma concentration; C<sub>min</sub>, minimum steady-state concentration; QD, once daily; BID, twice daily



#### 7 Thrombosis and Haemostasis 2010;104:633-641

## **Renal impairment increases exposure to edoxaban**




Time post-dose (hour)

|                               | Renal function group |                                |                                    |                                  |                              |  |
|-------------------------------|----------------------|--------------------------------|------------------------------------|----------------------------------|------------------------------|--|
|                               | Healthy<br>(n=8)     | Mild renal impairment<br>(n=8) | Moderate renal impairment<br>(n=8) | Severe renal impairment<br>(n=8) | Peritoneal dialysis<br>(n=8) |  |
| AUC <sub>0-24</sub> (ng•h/mL) | 419 (90.3)           | 581 (126)                      | 720 (175)                          | 700 (156)                        | 879 (311)                    |  |
| AUC <sub>0-24</sub> (norm)    | 5.86 (1.98)          | 7.56 (0.94)                    | 9.85 (3.72)                        | 10.1 (3.15)                      | 13.5 (5.88)                  |  |
| $AUC_{0-\infty}$ (ng•h/mL)    | 453 (102)            | 636 (152)                      | 816 (209)                          | 857 (199)                        | 1031 (377)                   |  |
| $AUC_{0-\infty}$ (norm)       | 6.35 (2.22)          | 8.24 (1.00)                    | 11.2 (4.38)                        | 12.3 (3.60)                      | 157 (6.90)                   |  |

All results are presented as the arithmetic mean (SD) except for  $T_{max}$ , which is presented as the median (range). PK parameters normalized for body weight (kg) are indicated by (norm).

Ridout et al. Poster presented at Am Coll Clin Pharm/Eur Soc Clin Pharm 2009<sup>8</sup>


# Simulation of impact of P-gp inhibitors on edoxaban exposure



Keto=ketoconazole; Quin=quinidine ; Ery=erythromycin; Amio=amiodarone ; Verap=verapamil

## Impact of body weight on safety of edoxaban


• Data taken from a safety study of edoxaban in 536 Japanese AF patients



## Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation



## ENGAGE AF-TIMI 48 —the Largest and Longest Clinical Trial Among NOACs'<sup>1,2</sup>



<sup>a</sup> Nonvalvular atrial fibrillation.

- <sup>b</sup> A validated measure for assessing stroke risk. The CHADS<sub>2</sub> scoring is calculated by assigning 1 point each for a history of congestive heart failure, hypertension, age ≥75 years, or diabetes mellitus and by assigning 2 points for history of stroke or transient ischemic attack.<sup>1</sup>
- <sup>c</sup> Twenty-three patients in the LIXIANA® 60/30 mg treatment arm and 24 patients in the warfarin arm did not receive study drug, resulting in 7012 patients included in each arm of the safety analysis, which reflects the on-treatment period.<sup>1</sup> There were 32 patients in the LIXIANA® 30/15 mg treatment arm who did not receive study drug, resulting in 7002 patients in the safety analysis, which reflects the on-treatment period.
- d International normalized ratio.1
- The LIXIANA® 30/15 mg dosage is not approved for use.

1. Giugliano RP et al. N Engl J Med. 2013;369(22):2093-2104. 2. Ruff CT et al. Lancet. 2014;383(9921):955-962.

3. Giugliano RP et al. N Engl J Med. 2013;369(22):Supplemental Appendix.

### **ENGAGE AF-TIMI 48 Prospectively Accounted for Managing** Patients With Clinical Factors That Increase Bleeding Risk

Edoxaban dose was halved from 60 to 30 mg or from 30 to 15 mg QD.

- <u>At randomization</u>:
  - CrCl 30-50 mL/min
  - Body weight ≤60 kg
  - Concomitant use of specific P-gp inhibitor (quinidine, verapamil, dronedarone)\*

### • During study:

- CrCl 30–50 mL/min and >20% drop from baseline
- Body weight ≤60 kg and >10% drop from baseline
- Concomitant use of specific P-gp inhibitors (quinidine, verapamil, dronedarone)\*

## Primary efficacy and safety outcome measures

### • Primary efficacy

- Time to first stroke (ischemic or hemorrhagic) or SEE
- Principal safety
  - -Major bleeding as defined by ISTH
    - Fatal bleeding, and/or
    - Symptomatic bleeding in a critical area or organ such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or
    - Bleeding causing a fall in hemoglobin level of 2 g/dL or more, or leading to transfusion of two or more units of whole blood or red cells

## **Inclusion Criteria**

- Male or female patients, age ≥21 years
- Written informed consent provided
- History of AF documented by an electrical tracing within the prior12 months and for which anticoagulation is indicated and planned for the duration of the study
  - Including paroxysmal, persistent or permanent AF
  - Including subjects with or without previous VKA experience

## • CHADS<sub>2</sub> risk score ≥2


- Patients score 1 point for presence of congestive heart failure, hypertension (>140/90 or medically treated), age ≥75 years or diabetes mellitus
- Patients score 2 points for having a prior stroke or transient ischemic attack

## **Key exclusion Criteria**

- Transient AF secondary to other reversible disorders
- Severe renal insufficiency (calculated CrCl <30 mL/min)
- High risk of bleeding due to concomitant conditions e.g. history of intracranial, intraocular, spinal, retroperitoneal, or intra-articular bleeding; overt gastrointestinal bleeding or active ulcer within the previous year; recent severe trauma, major surgery, or deep organ biopsy within the previous 10 days
- Dual-antiplatelet therapy (e.g., aspirin plus thienopyridine) or anticipated need to receive such therapy
- Moderate or severe mitral stenosis, unresected atrial myxoma, or a mechanical heart valve
- Acute MI, stroke, acute coronary syndrome, or percutaneous coronary intervention within the previous 30 days
- Subjects who are unlikely to comply with the protocol


Giugliano et al. N Engl J Med. 2013;369(22):2093-2104

## **Populations/Analysis definition**



Giugliano et al. N Engl J Med. 2013;369(22):2093-2104

## **Global participants**



## **Patients Characteristics**

| Characteristic   | Warfarin<br>(n=7,036)  | Edoxaban 60/30 mg<br>(n=7,035)   |
|--|--|--|
| Median age [IQR], years  | 72 [64–78]   | 72 [64–78]   |
| Female sex , n (%)   | 2,641 (37.5)   | 2,669 (37.9)   |
| Region, n (%)<br>North America<br>Latin America<br>Western Europe<br>Eastern Europe<br>Asia Pacific and South Africa   | 1,562 (22.2)<br>888 (12.6)<br>1,078 (15.3)<br>2,381 (33.8)<br>1,127 (16.0)   | 1,559 (22.2)<br>886 (12.6)<br>1,079 (15.3)<br>2,383 (33.9)<br>1,128 (16.0)   |
| Paroxysmal atrial fibrillation, n (%)  | 1,778 (25.3)   | 1,753 (24.9)   |
| Qualifying risk factors, n (%)<br>Age ≥75 years<br>Prior stroke or transient ischemic attack<br>Chronic heart failure<br>Diabetes mellitus<br>Hypertension requiring treatment | 2,820 (40.1)<br>1,991 (28.3)<br>4,048 (57.5)<br>2,521 (35.8)<br>6,588 (93.6) | 2,848 (40.5)<br>1,976 (28.1)<br>4,097 (58.2)<br>2,559 (36.4)<br>6,591 (93.7) |


## **Patients Characteristics**

| Characteristic  | Warfarin<br>(n=7,036)  | Edoxaban 60/30 mg<br>(n=7,035)  |
|---|--|---|
| CHADS <sub>2</sub> , mean±SD, n (%)<br>≤3<br>4–6  | <mark>2.8</mark> ±1.0<br>5,445 (77.4)<br>1,591 (22.6)                  | <b>2.8</b> ±1.0<br>5,422 (77.1)<br>1,613 (22.9)                       |
| Dose reduction at randomization*, n (%)<br>Creatinine clearance 30–50 mL/min<br>Weight ≤60 kg<br>Verapamil or quinidine     | 1,787 ( <mark>25.4</mark> )<br>1,361 (19.3)<br>701 (10.0)<br>243 (3.5) | 1,784 ( <mark>25.4</mark> )<br>1,379 (19.6)<br>684 (9.7)<br>258 (3.7) |
| Previous vitamin K antagonist for ≥60 days, n (%)   | 4,138 (58.8)   | 4,140 (58.8)  |
| Medications at time of randomization, n (%)<br>Aspirin<br>Thienopyridine<br>Amiodarone<br>Digoxin or digitalis preparations | 2,092 (29.7)<br>164 (2.3)<br>827 (11.8)<br>2,176 (30.9)                | 2,070 (29.4)<br>174 (2.5)<br>866 (12.3)<br>2,078 (29.5)               |

\*Patients with CrCl 30–50 mL/min, body weight ≤60 kg or those receiving concomitant strong P-gp inhibitors (verapamil, quinidine or dronedarone) at randomization received a 50% reduction in the dose of edoxaban to maintain similar exposure to the patient with out these factors

## ENGAGE AF-TIMI 48 Broad Range of Patients <sup>1,2</sup>

#### PERCENTAGE<sup>a</sup> OF PATIENTS (N=21,105) WITH COMORBIDITIES OR OTHER FACTORS<sup>1,2</sup>




<sup>a</sup> Percentages are approximate. <sup>b</sup> Mean CHADS<sub>2</sub> score in the trial was 2.8. <sup>c</sup> Congestive heart failure. <sup>d</sup> Transient ischemic attack. <sup>e</sup> Myocardial infarction. <sup>f</sup>~32% of patients (~25% [n=5356] at randomization, and an additional ~7% [n=1477] during the trial) received a dose reduction (half-dose). <sup>g</sup> Creatinine clearance. <sup>h</sup> P-glycoprotein. <sup>i</sup> Verapamil, dronedarone, or quinidine.

1. Giugliano RP et al. N Engl J Med. 2013;369(22):2093-2104. 2. Giugliano RP et al. N Engl J Med. 2013;369(22):Supplemental Appendix.


## **Comparison of 4 NOACs' phase 3 trials**

| Study characteristics                | RE-LY<br>(Dabigatran)         | ROCKET-AF<br>(Rivaroxaban) | ARISTOTLE<br>(Apixaban) | ENGAGE-AF<br>(Edoxaban) |  |  |  |  |
|--------------------------------------|-------------------------------|----------------------------|-------------------------|-------------------------|--|--|--|--|
| Medication                           | Medication                    |                            |                         |                         |  |  |  |  |
| Aspirin, %                           | 39.8                          | 36.5                       | 30.9                    | 29.3                    |  |  |  |  |
| Vitamin K antagonist, %              | 49.6                          | 62.4                       | 57.2                    | 58.9                    |  |  |  |  |
| TTR, %<br>(obtained in warfarin arm) | 64                            | 55                         | 62                      | 68                      |  |  |  |  |
| Endpoint crude event rates (%/       | yr)(obtained in warfarin arm) |                            |                         |                         |  |  |  |  |
| Stroke or SE                         | 1.7                           | 2.4                        | 1.6                     | 1.8                     |  |  |  |  |
| Death from any cause                 | 4.3                           | 2.2*                       | 3.9                     | 4.4                     |  |  |  |  |
| Myocardial infarction                | 0.5                           | 1.1*                       | 0.6                     | 0.8                     |  |  |  |  |
| ISTH major bleeding                  | 3.4*                          | 3.4*                       | 3.1*                    | 3.4*                    |  |  |  |  |


## Primary Efficacy Endpoint Stroke and Systemic Embolism



## Primary Safety Endpoint Major bleeding



## Once-daily Edoxaban Was Comparable to Warfarin in <u>Reducing Stroke/SEE Risk<sup>1</sup></u>



<sup>9</sup> Confidence interval.

#### Giugliano et al. N Engl J Med. 2013;369(22):2093-2104

# Once-daily Edoxaban Was Comparable to Warfarin in <u>Reducing Stroke/SEE Risk<sup>1</sup></u>

| Outcome                   |      | Warfarin<br>(n=7,036) |     | kaban<br>60 mg<br>7,035) | Edoxaban 60/30 mg<br>versus warfarin |       |
|---------------------------|------|-----------------------|-----|--------------------------|--------------------------------------|-------|
|                           | n    | %/yr                  | n   | %/yr                     | HR (95% CI)                          | Р     |
| Stroke, SEE, CV death     | 831  | 4.43                  | 728 | 3.85                     | 0.87 (0.78–0.96)                     | 0.005 |
| MACE                      | 926  | 4.98                  | 827 | 4.41                     | 0.88 (0.81–0.97)                     | 0.01  |
| Stroke, SEE or death      | 1046 | 5.57                  | 949 | 5.01                     | 0.90 (0.82–0.98)                     | 0.02  |
| Death or ICH              | 926  | 4.88                  | 817 | 4.27                     | 0.87 (0.79–0.96)                     | 0.004 |
| Death or disabling stroke | 878  | 4.61                  | 812 | 4.24                     | 0.92 (0.83–1.01)                     | 0.08  |
|                           |      |                       |     |                          |                                      |       |
| All-cause mortality       | 839  | 4.35                  | 773 | 3.99                     | 0.92 (0.83–1.01)                     | 0.08  |
| CV death                  | 611  | 3.17                  | 530 | 2.74                     | 0.86 (0.77–0.97)                     | 0.013 |
| Myocardial infarction     | 141  | 0.75                  | 133 | 0.70                     | 0.94 (0.74–1.19)                     | 0.60  |

### Once-daily Edoxaban Demonstrated Consistent Efficacy Results Across a Broad Range of NVAF Patients<sup>1,2</sup>

#### Stroke and SEE across major subpopulations (overall study period)<sup>13</sup>

| Subgroups   | Patients (n) <sup>ь</sup> | LIXIANA®<br>% of patients with event/yr | HR <sup>d</sup> and 95% Cl <sup>e</sup> | Warfarin<br>% of patients with event/yr |
|---|---------------------------|---|---|---|
| CHADS <sub>2</sub> score <sup>f</sup>               |                           |   |   |   |
| ≤3  | 16,337                    | 1.32                                    |   | 1.48                                    |
| >3  | 4768                      | 2.46                                    |   | 3.00                                    |
| Hypertension  | 19,754                    | 1.51                                    | <b>└────</b> ┤                          | 1.80                                    |
| CHF   | 12,124                    | 1.59                                    |   | 1.82                                    |
| Elderly (≥75 yrs)                                   | 8474                      | 1.91                                    |   | 2.31                                    |
| Diabetes  | 7624                      | 1.42                                    |   | 1.52                                    |
| Prior stroke/TIA                                    | 5973                      | 2.44                                    |   | 2.85                                    |
| Prior MI  | 2433                      | 1.72                                    | •                                       | 2.18                                    |
| Concomitant aspirin use at baseline                 | 6180                      | 1.54                                    |   | 2.23                                    |
| <sup>a</sup> Events that occurred from randomizatio | en to and of              | 0.5                                     | 1<br>Ne hattar                          | 2                                       |
| * Events that occurred from randomizatio            | in to end of              |   | N <sup>®</sup> better War               | farin better→                           |

Events that occurred from randomization to end of treatment period.

<sup>b</sup> Reflects combined number of patients from all 3 treatment arms.

° Includes patients taking LIXIANA® 60 mg and those dose-


<sup>d</sup> Hazard ratio.

Confidence interval.

<sup>f</sup> A validated measure for assessing stroke risk. The CHADS<sub>2</sub> scoring is calculated by assigning 1 point each for a history of congestive heart failure, hypertension, age ≥75 years, or diabetes mellitus and by assigning 2 points for history of stroke or transient ischemic attack.

reduced to 30 mg.

# Once-daily Edoxaban Was Superior to Warfarin in <u>Reducing Major Bleeding Risk</u><sup>1</sup>



<sup>e</sup> Confidence interval

#### Giugliano et al. N Engl J Med. 2013;369(22):2093-2104

<sup>b</sup> Includes patients talking LIXIANA 60 mg and those dose-reduced to 30mg

<sup>d</sup> Hazard ratio

<sup>a</sup> Time from first dose of study drug to last does plus 3 days

<sup>c</sup> Relative risk reduction

### Once-daily Edoxaban Was Associated With Significantly Lower Rates of bleeding Compared With Warfarin<sup>1</sup>

#### Key bleeding outcomes in ENGAGE AF-TIMI 48 (On-treatment period<sup>a</sup>)<sup>1</sup>

|                           | LIXIANA® <sup>b</sup><br>(n=7012) | Warfarin<br>(n=7012) | Relative<br>Risk<br>Reduction | HR <sup>°</sup> and 95% Cl <sup>d</sup>            |
|---------------------------|-----------------------------------|----------------------|-------------------------------|--|
| Intracranial bleeding     | <b>0.39</b><br>(n=61)             | 0.85<br>(n=132)      | 53%                           | HR, 0.47; 95% CI,<br>0.34 to 0.63; <i>P</i> <0.001 |
| Life-threatening bleeding | <b>0.40</b><br>(n=62)             | 0.78<br>(n=122)      | 49%                           | HR, 0.51; 95% Cl,<br>0.38 to 0.70; <i>P</i> <0.001 |
| Fatal bleeding            | <b>0.21</b><br>(n=32)             | 0.38<br>(n=59)       | 45%                           | HR, 0.55; 95% CI,<br>0.36 to 0.84; <i>P</i> =0.006 |

• The rate of major gastrointestinal bleeding was higher in patients taking LIXIANA<sup>®</sup> compared with those taking warfarin (1.51% per year vs 1.23% per year, respectively; HR, 1.23; 95% CI, 1.02 to 1.50; *P*=0.03)<sup>1</sup>


<sup>a</sup> Time from first dose of study drug to last does plus 3 days

<sup>b</sup> Includes patients talking LIXIANA 60 mg and those dose-reduced to 30mg


<sup>c</sup> Hazard ratio <sup>d</sup> Confidence interval

Giugliano et al. N Engl J Med. 2013;369(22):2093-2104


## Once-daily Edoxaban Was Superior to Warfarin in Reducing the Risk of Major Bleeding in <u>renal impairment pts.</u>




## Once-daily Edoxaban Was Superior to Warfarin in Reducing the Risk of Major Bleeding in <u>low body weight pts.</u>



## Event rate by age (Warfarin only)




## Event rate by age



## The Primary <u>Net Clinical Outcome<sup>1</sup></u>

#### Net Clinical Outcome (overall study period<sup>a</sup>)<sup>1</sup> Stroke/SE/Major bleeding/Death




<sup>a</sup> Event that occurred from randomization to end of treatment period <sup>b</sup> Includes paients taking LIXIANA 60 mg and those dose reduced to 30mg <sup>c</sup> Hazard ratio <sup>d</sup> Confidence interval.

#### Giugliano et al. N Engl J Med. 2013;369(22):2093-2104

## <u>Efficacy</u> in Patients With Factors That Increase the Risk of Bleeding Who Were <u>Dose-reduced to Edoxaban 30 mg</u><sup>1</sup>

#### Stroke/SEE (overall study period)<sup>1</sup>



<sup>a</sup> All randomized subjects who received at least 1 dose of randomized drug and did not have any major protocol violations

<sup>b</sup> Hazard ratio <sup>c</sup> Confidence interval


<sup>d</sup> Creatinine clearance.

<sup>†</sup>Verapamil, dronedarone, or quinidine.

1. LIXIANA Summary of Product Characteristics 2014. Daiichi Sankyo Europe GmbH.

### <u>Major Bleeding</u> Compared With Warfarin in Patients Who Were <u>Dose-reduced to Edoxaban 30 mg<sup>1</sup></u>


Major bleeding (on-treatment period)<sup>1</sup>



a Time from first dose of study drug to last dose plus 3 days. b Relative risk reduction. c Hazard ratio. d Confidence interval. \* Creatinine clearance. † Verapamil, dronedarone, or quinidine.

1. LIXIANA Summary of Product Characteristics 2014. Daiichi Sankyo Europe GmbH .

### **CV mortality (ITT Overall)**



### Edoxaban 60/30mg is approved and 30/15mg is not approved

|                        | HD edoxaban vs warfarin           |                              |                          | LD edoxaban vs warfarin           |                              |                          |
|------------------------|-----------------------------------|------------------------------|--------------------------|-----------------------------------|------------------------------|--------------------------|
|                        | No dose reduction,<br>HR (95% CI) | Dose reduced,<br>HR (95% CI) | P <sub>interaction</sub> | No dose reduction,<br>HR (95% CI) | Dose reduced,<br>HR (95% CI) | p <sub>interaction</sub> |
| Stroke or SEE          | 0·78<br>(0·61–0·99)               | 0·81<br>(0·58–1·13)          | 0.85                     | 1·07<br>(0·86–1·34)               | 1·07<br>(0·79–1·46)          | 0.99                     |
| lschaemic<br>stroke    | 0·94<br>(0·70–1·24)               | 0·96<br>(0·63-1· <b>4</b> 6) | 0.91                     | 1·43<br>(1·11-1·85)               | 1·79<br>(1·25-2·58)          | 0.32                     |
| All-cause<br>mortality | 0·94<br>(0·76–1·17)               | 0·85<br>(0·62–1·17)          | 0.59                     | 0·79<br>(0·63-0·99)               | 0·94<br>(0·69–1·28)          | 0.37                     |
| Major bleed            | 0·88<br>(0·76–1·03)               | 0·63<br>(0·50-0·81)          | 0.023                    | 0·55<br>(0·46–0·65)               | 0·31<br>(0·23-0·42)          | 0.002                    |
| Fatal bleed            | 0·61<br>(0·35–1·07)               | 0·46<br>(0·23-0·92)          | 0.54                     | 0·51<br>(0·28-0·91)               | 0·15<br>(0·05–0·43)          | 0.044                    |
| ІСН                    | 0·47<br>(0·32–0·68)               | 0·46<br>(0·27-0·78)          | 0.94                     | 0·40<br>(0·27–0·60)               | 0·11<br>(0·04-0·28)          | 0.011                    |
| GI bleed               | 1·32<br>(1·06–1·65)               | 1·00<br>(0·67-1·47)          | 0.21                     | 0·70<br>(0·54–0·91)               | 0·57<br>(0·36–0·89)          | 0.43                     |

HD=higher dose. LD=low dose. HR=hazard ratio. SEE=systemic embolic event. ICH=intracranial haemorrhage. Gl=gastrointestinal.

Table 2: Relative efficacy and safety of edoxaban compared with warfarin stratified by dose reduction status

#### http://dx.doi.org/10.1016/ S0140-6736(14)61943-7




- Once-daily regimens of edoxaban (60/30 mg) were noninferior to warfarin with respect to the prevention of stroke or systemic embolism
- and were associated with significantly lower rates of bleeding and death from cardiovascular causes.

### Edoxaban versus Warfarin in Asian Patients : A Subgroup Analysis of the ENGAGE AF-TIMI 48 Trial

### **Patients disposition**


warfarin



## **Baseline Demographics and Characteristics**

|  | East Asian (n=1,943) | Non-East Asian (n=19,162) |  |
|--|----------------------|---------------------------|--|
| Age, y, median                               | 71                   | 72                        |  |
| Females, n (%)                               | 545(28.0)            | 7495(39.1)                |  |
| Weight, kg, mean                             | 67.0                 | 85.6                      |  |
| Paroxysmal AF, n (%)                         | 373(19.2)            | 4993(26.1)                |  |
| CHADS2 score, mean±SD                        | 2.9±1.0              | 2.8±1.0                   |  |
| ≤3 <i>,</i> n (%)                            | 1487(76.5)           | 14850(77.5)               |  |
| 4-6, n (%)                                   | 456(23.5)            | 4312(22.5)                |  |
| Dose reduction at randomization, n (%)       | 912( <b>46.9</b> )   | 4444( <mark>23.2</mark> ) |  |
| CrCl≤50mL/min, n (%)                         | 583( <b>30.0</b> )   | 3491(18.2)                |  |
| weight≤60kg, n (%)                           | 594(( <b>30.6</b> )  | 1489(7.8)                 |  |
| Use of verapamil or quinidine, n (%)         | 128 <b>(6.6)</b>     | 633(3.3)                  |  |
| Previous use of VKA for $\geq$ 60days, n (%) | 1153(59.3)           | 11288(58.9)               |  |
| Medication at time of randomization, n (%)   |                      |                           |  |
| Aspirin                                      | 543(27.9)            | 5637(29.4)                |  |
| Thienopyridine                               | 60(3.1)              | 427(2.2)                  |  |
| Amiodarone                                   | 85(4.4)              | 2407(12.6)                |  |
| Digoxine or digitalis preparation            | 576(29.6)            | 5751(30.0)                |  |


## **TTR for warfarin treated patients**






Non-East Asian


### **Primary Efficacy Endpoint (East Asian)**



## Primary Efficacy Endpoint (Stroke or SEE)



## Stroke (East Asian)




## Secondary Efficacy Endpoint

|  | East Asian            |       |         | Non-East Asian        |               |                 |  |
|--|-----------------------|-------|---------|-----------------------|---------------|-----------------|--|
|  | Hazard Ratio (95% CI) |       | P-value | Hazard Ratio (95% CI) |               | <i>P</i> -value |  |
| Stroke, SEE, or death from CV ca<br>Edoxaban 60 mg | iuses                 | 0.61  | 0.01    |                       | 0.89          | 0.03            |  |
| Edoxaban 30 mg                                     |                       | 0.93  | 0.67    | <b>Inde</b>           | 0.95          | 0.37            |  |
| Major adverse cardiac events                       |                       |       |         |                       |               |                 |  |
| Edoxaban 60 mg                                     |                       | 0.61  | 0.01    |                       | 0.91          | 0.05            |  |
| Edoxaban 30 mg                                     |                       | 0.92  | 0.62    |                       | 0.99          | 0.80            |  |
| Stroke, SEE, or death                              |                       |       |         |                       |               |                 |  |
| Edoxaban 60 mg                                     |                       | 0.64  | 0.01    | <b>•••</b>            | 0.92          | 0.08            |  |
| Edoxaban 30 mg                                     |                       | 0.87  | 0.37    | <b>100</b>            | 0.94          | 0.20            |  |
| Death, any cause                                   |                       |       |         |                       |               |                 |  |
| Edoxaban 60 mg                                     |                       | 0.63  | 0.04    |                       | 0.93          | 0.19            |  |
| Edoxaban 30 mg                                     |                       | 0.66  | 0.06    |                       | 0.88          | 0.02            |  |
| Death, CV causes                                   |                       |       |         |                       | 250           |                 |  |
| Edoxaban 60 mg 🛌                                   |                       | 0.46  | 0.01    |                       | 0.89          | 0.04            |  |
| Edoxaban 30 mg 🛛 🖡                                 |                       | 0.61  | 0.08    |                       | 0.87          | 0.02            |  |
| Myocardial infarction                              |                       | 0.83  | 0.72    |                       | 0.94          | 0.64            |  |
| Edoxaban 60 mg                                     |                       | 0.83  | 0.72    |                       | 1.22          | 0.09            |  |
| Edoxaban 30 mg 📕                                   |                       | 9.14  | 0.97    |                       | 1.22          | 0.09            |  |
|  | 0.5 1.0 1.5           | 20 25 | 0       | 0.5 1.0               | 1.5           | 2.0             |  |
| CV, cardiovascular,<br>SEE, systemic Edoxaba       | an better Warfarin be | tter  | 1       | Edoxaban better Wa    | rfarin better |                 |  |
| embolic event                                      |                       |       | <       |                       |               |                 |  |

Yamashita T, et al. Circ J. 2016 Feb 16. [Epub ahead of print] <sup>47</sup>

### Primary safety Endpoint (Major bleeding)





. In East Asian patients with AF, both doses of once-daily edoxaban:

- Reduce stroke and SEE similar to warfarin
- Reduce bleeding compared with warfarin
- Achieved results consistent with those outside East Asia

. Edoxaban 60/30mg regimen is effective and safe in the Asians.

### Relationship Between Edoxaban Dose, Concentration, Anti-Factor Xa Activity and Outcomes in the ENGAGE AF-TIMI 48 Trial

## Analysis of data from ENGAGE AF-TIMI 48 Trial: Overview

- Objective
- To correlate edoxaban dose, plasma concentration, and anti-factor Xa activity
- To compare efficacy and safety outcomes with warfarin stratified by dose reduction status
- Procedures
- Trough blood samples were collected 1 month after randomization.

### Edoxaban concentration (N=6,780)

measured by Quintiles Bio-analytical and ADME Laboratories

### Anti-factor Xa activity (N=2,865, sub-study)

measured by the Rotachrome Heparin assay on the Stago STAR Evolution platform


## **Edoxaban concentration & Anti-factor Xa activity**


### Edoxaban concentration

Dose reduction resulted in a decrease in mean exposure of 29% in the edoxaban 60/30 mg<sup>\*</sup> regimens.

### Anti-factor Xa activity

Dose reduction resulted in a decrease in mean anti-factor Xa activity by 25% in the edoxaban 60/30 mg\* regimens.






#### Figure 2: Mean trough anti-factor Xa activity


\*In the ENGAGE AF-TIMI 38, if patients randomized to edoxaban groups have an anticipated increased drug exposure (any one or multiple of the following: creatinine clearance [CrCl] 30-50 mL/min, body weight ≤60 kg, or concomitant administration of verapamil or quinidine [strong P-gp inhibitors]), they receive a 50% dose reduction (60 mg reduced to 30 mg).

### **Edoxaban concentration & Anti-factor Xa activity**






### <Stroke /SEE>



\*In the ENGAGE AF–TIMI 38, if patients randomized to edoxaban groups have an anticipated increased drug exposure (any one or multiple of the following: creatinine clearance [CrCl] 30-50 mL/min, body weight ≤60 kg, or concomitant administration of verapamil or quinidine [strong P-gp inhibitors]), they receive a 50% dose reduction (60 mg reduced to 30 mg).

54

### <Major bleeding>




\*In the ENGAGE AF–TIMI 38, if patients randomized to edoxaban groups have an anticipated increased drug exposure (any one or multiple of the following: creatinine clearance [CrCl] 30-50 mL/min, body weight ≤60 kg, or concomitant administration of verapamil or quinidine [strong P-gp inhibitors]), they receive a 50% dose reduction (60 mg reduced to 30 mg).

55

### **Clinical outcomes & Edoxaban trough concentration**

- Therapeutic window of edoxaban
  - Major bleed: narrower (steeper) / Stroke or SEE: wider (shallower)/ ICH: widest (nearly flat)

Probability of clinical outcomes versus edoxaban concentration





- Strategy of tailoring of the edoxaban dose on the basis of clinical factors achieved the dual goal of preventing excess drug concentrations and optimizing an individual patient's risk of ischemic and bleeding events.
- Therapeutic window for edoxaban is narrower for major bleeding than thromboembolism.
- Edoxaban 60/30mg regimen is effective and safe

# Take Home Messages

- Once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism
- and were associated with significantly lower rates of bleeding and death from cardiovascular causes.
- Edoxaban was effective and safe in the Asians.
- Strategy of tailoring of the edoxaban dose on the basis of **clinical** factors was effective and safe.